CRL
Charles River Laboratories Inte · Healthcare · Diagnostics & Research
TECHStrong BuyZACKSBuy
R500#125 today
$290.19
+1.17% today · -0.90% 1W
Oct 2 close or latest
PreviewWhy it's moving
Moving with the market
- CRL +1.17% on the last session vs SPY +0.74%: +0.4 pts of stock-specific move.
- Aftermath, big drop (Oct 1): After its 58 big drops in the past 5 years, CRL typically gained 0.4% over the next day (median) and was higher 60% of the time; half the outcomes fell between -0.7% and +1.5%. An ordinary day: -0.0%. Among S&P 500 stocks after big drops, that ranks #139 of 500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Key facts
- Market cap
- $14.0B
- Held by institutions
- 122.8%
- Short interest
- 5.4%
- 52-week range
- 146.20–303.31
- Analyst mean target
- —
- Next earnings
- Nov 4 est.
- Forward P/E
- 22.8
Recent events
Earnings ▲
2Q2026 results: EPS $3.02 vs $2.74 expected beat +$0.28 (+10.3%); revenue $1.0B; next session +11.4% (+11.6 vs SPY)Earnings ▲
1Q2026 results: EPS $2.06 vs $1.95 expected beat +$0.11 (+5.4%); revenue $995.8M; next session 0.0% (+0.3 vs SPY)Earnings ▲
4Q2025 results: EPS $2.39 vs $2.35 expected beat +$0.04 (+1.9%); revenue $994.2M; next session -0.3% (-0.8 vs SPY)Earnings ▲
3Q2025 results: EPS $2.43 vs $2.34 expected beat +$0.09 (+3.9%); revenue $1.0B; next session -5.7% (-6.1 vs SPY)